Skip to main content
Erschienen in: International Journal of Hematology 5/2008

01.12.2008 | Original Article

Risk factors of long-term incidences of thrombosis, myelofibrosis and evolution into malignance in polycythemia vera: a single center experience from China

verfasst von: Jie Bai, Yangping Xue, Lei Ye, Jianfeng Yao, Chunlin Zhou, Zonghong Shao, Linsheng Qian, Renchi Yang, Haiyan Li, Hongyun Zhang, Yizhou Zheng

Erschienen in: International Journal of Hematology | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

To find out risk factors of incidences of long-term complications of thrombosis, myelofibrosis with myeloid metaplasia (MMM) and evolution into malignance in Chinese PV patients, we evaluated 320 PV patients referred to our center from April 1984 to June 2005 by Kaplan–Meier estimation and Cox proportional hazards models. A total of 250 events of thrombosis were observed in 138 (43.13%) patients. Advanced age, prior thrombosis and hemoglobin out of control were statistically significant risk factors of incidences of thrombotic events. A total of 43 patients progressed into MMM at a median time of 84 (7–240) months, higher white blood cell (WBC) count, splenomegaly, receiving alkylating agent and hydroxycarbamide were associated with the progression into MMM. During the follow-up time, 11 and 2 patients died of fatal complications of thrombosis and acute myeloid leukaemia (AML), respectively. These results suggest that advanced age, prior thrombosis and hemoglobin out of control contributed to relatively high incidence of thromboembolism; higher WBC count, splenomegaly, receiving alkylating agent and hydroxycarbamide were risk factors of evolution to MMM. The main poor factors that influenced the survival of Chinese PV patients were incidences of thromboembolism and evolution into AML.
Literatur
1.
Zurück zum Zitat Chim CS, Kwong YL, Chan PT, Liang R. Polycythemia vera in Chinese patients: thirty-six years of experience. Am J Hematol. 1997;56:59–62. doi:10.1002/(SICI)1096-8652(199709)56:1<59::AID-AJH12>3.0.CO;2-Y.CrossRefPubMed Chim CS, Kwong YL, Chan PT, Liang R. Polycythemia vera in Chinese patients: thirty-six years of experience. Am J Hematol. 1997;56:59–62. doi:10.1002/(SICI)1096-8652(199709)56:1<59::AID-AJH12>3.0.CO;2-Y.CrossRefPubMed
3.
Zurück zum Zitat Najean Y, Rani JD. The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin Hematol. 1997;34:6–16.PubMed Najean Y, Rani JD. The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin Hematol. 1997;34:6–16.PubMed
4.
Zurück zum Zitat Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica. 2003;88:13–8.PubMed Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica. 2003;88:13–8.PubMed
5.
Zurück zum Zitat Chievitz E, Thiede T. Complication and causes of death in polycythemia vera. Acta Med Scand. 1962;172:513–23.CrossRefPubMed Chievitz E, Thiede T. Complication and causes of death in polycythemia vera. Acta Med Scand. 1962;172:513–23.CrossRefPubMed
6.
Zurück zum Zitat Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NT, Wasserman LR. Therapeutic recommendations in polycytheia vera based on polycythemia vera study group protocols. Semin Hematol. 1986;23:132–43.PubMed Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NT, Wasserman LR. Therapeutic recommendations in polycytheia vera based on polycythemia vera study group protocols. Semin Hematol. 1986;23:132–43.PubMed
7.
Zurück zum Zitat Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer. 1991;67:2658–63. doi:10.1002/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C.CrossRefPubMed Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer. 1991;67:2658–63. doi:10.1002/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C.CrossRefPubMed
8.
Zurück zum Zitat Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370–7.PubMed Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370–7.PubMed
10.
Zurück zum Zitat Weinfeld A, Swolin B, Westin J. Acute leukemia after hydroxyurea therapy in polycythemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol. 1994;52:134–9.CrossRefPubMed Weinfeld A, Swolin B, Westin J. Acute leukemia after hydroxyurea therapy in polycythemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol. 1994;52:134–9.CrossRefPubMed
14.
Zurück zum Zitat Polycythemia vera, Chronic idiopathic myelofibrosis, Acute myeloid leukaemia. In Pierre R, Imbert M, Thiele J, Brunning RD, Matutes E, Harris NL, et al., editors. World Health Organization classification of Tumours. lyon: IARC; 2001. pp. 32–75. Polycythemia vera, Chronic idiopathic myelofibrosis, Acute myeloid leukaemia. In Pierre R, Imbert M, Thiele J, Brunning RD, Matutes E, Harris NL, et al., editors. World Health Organization classification of Tumours. lyon: IARC; 2001. pp. 32–75.
17.
Zurück zum Zitat Landolfi R, Marchioli R, Kutti J, et al. European collaboration on low-dose aspirin in polycythemia vera investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114–24. doi:10.1056/NEJMoa035572.CrossRefPubMed Landolfi R, Marchioli R, Kutti J, et al. European collaboration on low-dose aspirin in polycythemia vera investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114–24. doi:10.​1056/​NEJMoa035572.CrossRefPubMed
18.
Metadaten
Titel
Risk factors of long-term incidences of thrombosis, myelofibrosis and evolution into malignance in polycythemia vera: a single center experience from China
verfasst von
Jie Bai
Yangping Xue
Lei Ye
Jianfeng Yao
Chunlin Zhou
Zonghong Shao
Linsheng Qian
Renchi Yang
Haiyan Li
Hongyun Zhang
Yizhou Zheng
Publikationsdatum
01.12.2008
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 5/2008
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-008-0188-y

Weitere Artikel der Ausgabe 5/2008

International Journal of Hematology 5/2008 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.